Key Takeaways
- • TA Associates is in advanced negotiations to acquire Advanced Medical Solutions (AMS), a UK-listed wound care and surgical dressing technology company, with a deadline to declare firm intention by May 16, 2026, under UK Takeover Code rules.
- • The reported offer price is 280 pence per share, valuing AMS at approximately £600 million ($809.52 million), according to Sky News—though AMS has not officially disclosed financial terms.
- • The transaction reflects ongoing private equity interest in London-listed companies seeking to capitalize on relatively subdued UK equity valuations following a wave of overseas buyout activity.
- • AMS has previously attracted private equity interest, including a reported approach from Bridgepoint, indicating sustained appeal to alternative investors in the tissue-healing and wound-care sector.
- • TA Associates demonstrates continued active deployment in UK healthcare and business services, having completed a $722 million acquisition of UK data and analytics firm FD Technologies in the prior year.
Summary
TA Associates, a US-based private equity firm, is in discussions to acquire Advanced Medical Solutions (AMS), a UK-listed developer and manufacturer of wound-care and surgical dressing technologies. The company confirmed engagement in takeover talks with TA Associates on Monday, April 21, 2026, though no financial terms have been formally disclosed by AMS itself.
According to Sky News reporting cited by both primary and supplemental sources, TA Associates is preparing an offer at 280 pence per share, which would value the British medical supplier at just over £600 million ($809.52 million). Under UK Takeover Code regulations, TA Associates must either formally declare a firm intention to proceed with an offer or withdraw by May 16, 2026—a mandatory disclosure deadline that structures the timeline for this transaction.
The potential acquisition aligns with a broader pattern of overseas private equity firms targeting London-listed companies to exploit comparatively subdued UK equity valuations. This latest bid reflects sustained buyout interest in the London market as alternative investors seek value opportunities. AMS is not a new target for PE interest; the company has previously attracted approaches from other buyout firms, including Bridgepoint, demonstrating consistent market appeal within the healthcare products and tissue-healing technology segment.
TA Associates has demonstrated consistent activity in the UK market, most notably completing a $722 million acquisition of FD Technologies, a British data and analytics firm, in the prior year. This track record indicates operational capacity and financial capability to execute mid-market acquisitions within the UK healthcare and services sectors. The potential AMS transaction, if completed, would expand TA Associates' portfolio within the specialized medical devices and wound-care segment, a therapeutic area with recurring revenue characteristics and demographic tailwinds from aging populations.
According to Sky News reporting cited by both primary and supplemental sources, TA Associates is preparing an offer at 280 pence per share, which would value the British medical supplier at just over £600 million ($809.52 million). Under UK Takeover Code regulations, TA Associates must either formally declare a firm intention to proceed with an offer or withdraw by May 16, 2026—a mandatory disclosure deadline that structures the timeline for this transaction.
The potential acquisition aligns with a broader pattern of overseas private equity firms targeting London-listed companies to exploit comparatively subdued UK equity valuations. This latest bid reflects sustained buyout interest in the London market as alternative investors seek value opportunities. AMS is not a new target for PE interest; the company has previously attracted approaches from other buyout firms, including Bridgepoint, demonstrating consistent market appeal within the healthcare products and tissue-healing technology segment.
TA Associates has demonstrated consistent activity in the UK market, most notably completing a $722 million acquisition of FD Technologies, a British data and analytics firm, in the prior year. This track record indicates operational capacity and financial capability to execute mid-market acquisitions within the UK healthcare and services sectors. The potential AMS transaction, if completed, would expand TA Associates' portfolio within the specialized medical devices and wound-care segment, a therapeutic area with recurring revenue characteristics and demographic tailwinds from aging populations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.